ImmunityBio (IBRX) vs Moderna (MRNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Moderna (MRNA) has outperformed ImmunityBio (IBRX) over the past year, gaining 605.6% versus a gain of 291.7%. Over five years, IBRX leads with a +6.6% price change compared with -39.2% for MRNA. Moderna is the larger company by market cap ($78.65 billion vs $10.50 billion), about 7.5 times the size, while ImmunityBio is growing revenue faster (+668.3% vs -39.9%).
Moderna converts more of its revenue into profit, with a net margin of -145.2% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | MRNA |
|---|---|---|
| Share price | $9.91 | $197.00 |
| Market cap | $10.50B | $78.65B |
| 1-day change | +1.64% | +0.26% |
| YTD return | +400.51% | +568.02% |
| 1-year return | +291.70% | +605.59% |
| 5-year return | +6.56% | -39.24% |
| EPS (TTM) | $-0.96 | $-7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $113.29M | $1.94B |
| Revenue growth (YoY) | +668.31% | -39.93% |
| Net income (latest FY) | $-351.40M | $-2.82B |
| Gross margin | 99.34% | 55.35% |
| Operating margin | -226.00% | -158.13% |
| Net margin | -310.18% | -145.16% |
| 52-week high | $12.43 | $212.22 |
| 52-week low | $1.95 | $22.28 |
| Distance from 52-week high | -20.27% | -7.17% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +28.66% | -38.58% |
| Average volume | 10.28M | 17.44M |
| Shares outstanding | 1.06B | 399.24M |
| Employees | 684 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Moderna is about 7.5 times larger than ImmunityBio by market value ($78.65B vs $10.50B).
- MRNA has outperformed IBRX by 313.9 percentage points over the past year.
- Moderna is more profitable, keeping -145.2 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs -39.93%).
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
IBRX vs MRNA FAQ
Which is bigger, ImmunityBio or Moderna?
Moderna (MRNA) is larger, with a market capitalization of $78.65B compared with $10.50B for ImmunityBio (IBRX).
Which stock has performed better over the past year, IBRX or MRNA?
MRNA returned +605.59% over the past 12 months, compared with +291.70% for IBRX (price return, excluding dividends). Past performance does not predict future results.
Are ImmunityBio and Moderna in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.